Glucoregulatory Consequences and Cardiorespiratory Parameters in Rats Exposed to Chronic–Intermittent Hypoxia: Effects of the Duration of Exposure and Losartan by Victor B. Fenik et al.
ORIGINAL RESEARCH ARTICLE
published: April 2012
doi: 10.3389/fneur.2012.00051
Glucoregulatory consequences and cardiorespiratory
parameters in rats exposed to chronic–intermittent
hypoxia: effects of the duration of exposure and losartan
Victor B. Fenik ,Tyana Singletary , Jennifer L. Branconi , Richard O. Davies and Leszek Kubin*
Department of Animal Biology 209E/VET, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA
Edited by:
Pierre-Charles Neuzeret, Lyon
Neuroscience Research Center,
France
Reviewed by:
Ramesh Vijay, University of Chicago
Medical Center, USA
Irma Gvilia, Ilia State University, USA
*Correspondence:
Leszek Kubin, Department of Animal
Biology 209E/VET, School of
Veterinary Medicine, University of
Pennsylvania, 3800 Spruce Street,
Philadelphia, PA 19104-6046, USA.
e-mail: lkubin@vet.upenn.edu
Background: Obstructive sleep apnea (OSA) is associated with glucose intolerance. Both
chronic sleep disruption and recurrent blood oxygen desaturations (chronic–intermittent
hypoxia, CIH) may cause, or exacerbate, metabolic derangements. Methods: To assess
the impact of CIH alone, without accompanying upper airway obstructions, on the counter-
regulatory response to glucose load and cardiorespiratory parameters, we exposed adult
male Sprague-Dawley rats to CIH or sham room air exchanges for 10 h/day for 7, 21, or
35 days and then, 1 day after conclusion of CIH exposure, conducted intravenous glucose-
tolerance tests (ivgtt) under urethane anesthesia. Additional rats underwent 35 days of CIH
followed by 35 days of regular housing, or had 35 day-long CIH exposure combined with
daily administration of the type 1 angiotensin II receptor antagonist, losartan (15mg/kg,
p.o.), and then were also subjected to ivgtt. Results: Compared with the correspond-
ing control groups, CIH rats had progressively reduced glucose-stimulated insulin release
and impaired glucose clearance, only mildly elevated heart rate and/or arterial blood pres-
sure and slightly reduced respiratory rate. The differences in insulin release between
the CIH and sham-treated rats disappeared in the rats normally housed for 35 days after
35 days of CIH/sham exposure. The losartan-treated rats had improved insulin sensitiv-
ity, with no evidence of suppressed insulin release in the CIH group. Conclusion: In
adult rats, the glucose-stimulated insulin release is gradually suppressed with the dura-
tion of exposure to CIH, but the effect is reversible. Elimination of the detrimental effect
of CIH on insulin release by losartan suggests that CIH disrupts glucoregulation through
angiotensin/catecholaminergic pathways. Accordingly, treatment with continuous positive
airway pressuremay ameliorate pre-diabetic conditions inOSApatients, in part, by reducing
sympathoexcitatory effects of recurrent nocturnal hypoxia.
Keywords: angiotensin II, blood pressure, diabetes, intravenous glucose-tolerance test, insulin, norepinephrine,
obstructive sleep apnea, sympathetic system
INTRODUCTION
In patients with obstructive sleep apnea (OSA), chronic noctur-
nal episodes of a transient loss of upper airway patency lead to
recurrent blood oxygen desaturations and sleep fragmentation.
Clinical studies show that such chronic, intermittent disruption of
both sleep and breathing has adverse consequences for cardiores-
piratory regulation, metabolism, and cognitive functions. OSA
patients are frequently obese, hypertensive, and glucose intoler-
ant – features typical of the metabolic syndrome (Peppard et al.,
2000; Newman et al., 2001; Tatsumi et al., 2005). Importantly,
recent association studies suggest that OSA is an independent risk
factor for glucose intolerance (Ip et al., 2002; Punjabi et al., 2002;
reviewed by Punjabi and Polotsky, 2005; Lévy et al., 2008; Tasali
and Ip, 2008), but the mechanistic bases linking different aspects
of sleep-disordered breathing to distinct cardiorespiratory, meta-
bolic, and other morbidities characteristic of OSA are still poorly
understood.
To elucidate the cellular and systemic pathophysiologic con-
sequences of OSA, rodents have been used to model, in a
controllable manner, conditions similar to those associated with
sleep-disordered breathing (e.g., Li et al., 1996, 2003, 2005; Lesske
et al., 1997; Carley and Radulovacki, 2002; Reeves et al., 2003; Zoc-
cal et al., 2007; Nair et al., 2011a). In particular, rodents exposed
to chronic–intermittent hypoxia (CIH) exhibit selected symptoms
typical of OSA patients (reviewed by Neubauer, 2001; Prabhakar
and Kumar, 2004); they have increased arterial blood pressure and
vascular reactivity (reviewed by Foster et al., 2007), increased sleep
propensity (Veasey et al., 2004), and impaired cognitive functions
(Li et al., 2003; Nair et al., 2011a). Normal mice exhibit insulin
resistance during acute exposure to intermittent hypoxia (Iiyori
et al., 2007). Leptin-deﬁcient mice exposed to CIH for 12weeks
have reduced glucose-tolerance (Polotsky et al., 2003), and healthy
humans acutely exposed to CIH have reduced insulin sensitivity
and impaired glucosedisposal (Louis andPunjabi,2009). Together,
these studies demonstrate that CIH alters glucose metabolism and
suggest that the effects of acute and chronic CIH are different
and that genetic background modiﬁes the effects of CIH on the
mechanisms of glucose disposal.
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Obstructive sleep apnea in humans and CIH in animal models
cause recurrent episodes of increased stimulation of the sym-
pathetic system and the associated elevation of catecholamines
and angiotensin II (Fletcher et al., 1992, 1999; Greenberg et al.,
1999; Iiyori et al., 2007; Gilmartin et al., 2010; Knight et al., 2011;
Tamisier et al., 2011). These sympathoexcitatory effects outlast the
period of acute disturbance of breathing and sleep (Knight et al.,
2011; Tamisier et al., 2011), and likely play a key role in the mul-
tiple cardiorespiratory and metabolic dysregulations associated
with OSA. Indeed, in addition to their blood pressure-elevating
actions, catecholamines, and angiotensin II acutely suppress the
counter-regulatory insulin response to high carbohydrate intake
and glucose disposal (Deibert and DeFronzo, 1980; Ogihara et al.,
2002; Vicini et al., 2002), and exacerbate the negative effects of
oxidative stress (Ogihara et al., 2002), which is a major pathogenic
factor in OSA (Prabhakar and Kumar, 2004; Nair et al., 2011a).
Furthermore, data from both rodents and healthy human sub-
jects indicate that systemic antagonism of type 1 angiotensin II
receptors attenuates the negative effects of CIH on arterial blood
pressure and sympathetic tone (Fletcher et al., 1999; Foster et al.,
2010; Marcus et al., 2010), and reduces insulin resistance in obese
Zucker rats (Henriksen et al., 2001).
Our main goals were to assess the time-course of changes in
glucose-stimulated insulin release following different periods of
exposure to CIH and determine whether the effects of CIH are
reversible when the animals are returned to normal housing. We
also set out to assess whether the angiotensin II type 1 recep-
tor antagonist, losartan, can ameliorate the adverse effects of CIH
on the counter-regulatory response to glucose load. Preliminary
reports have been published (Fenik et al., 2007; Kubin et al., 2008).
MATERIALS AND METHODS
ANIMALS AND EXPERIMENTAL GROUPS
Experiments were performed on 83 adult, male Sprague-Dawley
rats weighting 280–349 g at the beginning of the experimental pro-
tocol. Of those, 42 were subjected to CIH for periods of 7, 21, or
35 days and the remaining 41 to room air exchanges (sham treat-
ment) of matching durations. Of the 42 rats subjected to CIH, 9
underwent the treatment for 7 days, 7 for 21 days, 10 for 35 days, 10
for 35 days followed by normal housing for another 35 days, and
6 for 35 days with concomitant daily treatment with losartan (see
Table 1 for details). All rats were anesthetized on the day after the
last day of exposure and were subjected to intravenous glucose-
tolerance test (ivgtt). All procedures followed the guidelines for the
care and use of experimental animals established by the National
Institutes of Health and were approved by the Institutional Animal
Care and Use Committee of the University of Pennsylvania.
CHRONIC–INTERMITTENT HYPOXIA AND SHAM EXPOSURES
The animals were group-housed, two or three per standard cage,
under 12/12 h light/dark cycle (lights on at 7:00 a.m.), with stan-
dard chow diet (5001/AIN76; Purina), and water provided ad libi-
tum. The cages were placed inside 28.5 cm× 30.0 cm× 51.5 cm
chambers in which oxygen (O2) level was controlled by alternating
ﬂows of nitrogen (N2) and O2 (Oxycycler; Biospherix, Redﬁeld,
NY, USA). Sham-treated rats were housed in identical chambers
and experienced changes in ﬂow of compressed room air with Ta
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a timing that replicated gas ﬂows in one of the experimental
chambers. The O2 level in CIH chambers was nominally set to
cycle between 20.9% for 90 s and 10% for 90 s for 10 h/day from
7:00 a.m. to 5:00 p.m. daily (180 s cycle period). To accelerate gas
exchanges, an initial undershoot was applied at the onset of the
hypoxic half-cycle that transiently lowered O2 level to 7%, and
an overshoot was programmed-in at the onset of the normoxic
half-cycle that resulted in O2 level transiently reaching a peak of
24% (the O2 proﬁle used is illustrated in Rukhadze et al., 2010).
From 5:00 p.m. to 7:00 a.m., all chambers were ventilated with
a constant ﬂow of room air (to maintain normal levels of CO2
and humidity). An additional group of rats was ﬁrst exposed to
35 days of CIH or sham treatment and then observed for 35 days
under normal housing conditions before they were also subjected
to ivgtt. Another group of rats was exposed to CIH or sham treat-
ment and was additionally treated with losartan during the entire
period of exposure. The drug was administered daily at 10:00 a.m.
at a dose of 15mg/kg, p.o. Rats were brieﬂy immobilized in a trans-
parent restraining cone with an opening for the mouth, ∼0.2ml
suspension of the drug was pipetted into the mouth, and the ani-
mal was released into its home cage after it was veriﬁed that the
entire volume was ingested.
MEASUREMENTS DURING AND FOLLOWING CIH/SHAM EXPOSURES
The animalswere individuallyweighed at 5:00 p.m. every other day
throughout the experiment. In a subset of animals exposed to CIH
or sham treatment for 35 days, the amount of dry food consumed
during successive 2-day intervals was measured for each cage and
an average daily consumption per animal was calculated. After
the last day of exposure to CIH or sham treatment, the rats were
fasted overnight, anesthetized around 10:00 a.m. and subjected to
the ivgtt. The heart, left ventricle, and both adrenal glands were
extracted at the end of the acute experiment and weighed. The
average basal levels of glucose and insulin were determined from
up to three plasma samples collected prior to glucose bolus admin-
istration, and the basal c-peptide (the main insulin metabolite,
not to be confused with “c-reactive protein”) and corticosterone
were measured from one baseline sample each (see the sampling
schedule below). Plasma glucose levels were determined using a
colorimetric assay kit #510 (Sigma-Aldrich, Inc., Saint Louis, MO,
USA). Plasma insulin was measured using the rat insulin ELISA kit
#10-1137-99 (American Laboratory Products), c-peptide using kit
#RCP 21-K (RIA Linco Research) and corticosterone using ELISA
kit #AC-14F1 (Immunodiagnostic Systems).
ADMINISTRATION OF THE INTRAVENOUS GLUCOSE-TOLERANCE TEST
Rats were fasted overnight, pre-anesthetized with isoﬂurane (2–
3%) and anesthetized with urethane (1 g kg−1, i.p., supplemented
by 40mg i.v. injections, as needed). A femoral artery and vein were
cannulated for arterial blood pressure monitoring and ﬂuid injec-
tions, respectively. Rectal temperature was measured and main-
tained at 37˚C with a servo-controlled heating pad. For the test, a
glucose bolus (400mg/kg) was injected intravenously over 1min.
Sixteen blood samples were collected from the femoral artery, the
ﬁrst one right after cannulation (marked as negative 20min on
the graphs) and the remaining ones at the following times relative
to the start of glucose injection (in min): −5, −2, 1, 2, 3, 5, 7,
9, 11, 13, 15, 17, 25, 40, and 70. The volumes were 0.1ml for all
samples except the ﬁrst and the second (−5min) that were 0.35ml
for the additional measurements of c-peptide and corticosterone
and determination of the hematocrit. The total volume of blood
drawn during ∼1.5 h was 2.1ml. All blood samples were spun
immediately after collection, aliquoted, and stored at −80˚C.
STATISTICAL ANALYSIS
Statistical analysis was performed using SigmaStat v. 12 (Jan-
del, San Raphael, CA, USA). All data sets were ﬁrst subjected to
Shapiro–Wilk normality test. The variables that were normally
distributed were then analyzed with two-way analysis of variance
(ANOVA) with Holm–Sidak correction, with one factor being the
treatment (CIH or sham) and the other the duration of exposure
(7, 21, 35 days, or 35 days followed by 35 days of normal housing).
ANOVA was followed by individual two-tailed Student’s t -tests
of the effects of the treatment within each group or the effect
of exposure duration between groups. The data sets that were
not normally distributed were subjected to Mann–Whitney rank
sum tests of differences between treatments and across exposure
durations. Effects were regarded signiﬁcant when p< 0.05. The
variability of the means is characterized by the standard error (SE)
throughout the report.
RESULTS
FOOD CONSUMPTION AND BODY AND ORGAN WEIGHTS DURING AND
FOLLOWING EXPOSURE TO CIH
After the ﬁrst 2 days of exposure to CIH, all animals had a steady
increase of body weight during the exposures. However, the rate
of body weight gain was signiﬁcantly slower in the CIH than
sham-treated rats. Within the groups exposed to CIH/sham treat-
ment for 7, 21, or 35 days, two-way ANOVA revealed signiﬁcant
effects of both treatment (p< 0.001, F1,2,46 = 13.15) and duration
of exposure (p< 0.001, F1,2,46 = 8.41), and post hoc comparisons
within each exposure group indicated signiﬁcantly lower daily
body weight gains in the CIH rats (Table 1). The reduced body
weight gain in CIH rats was not associated with reduced food
consumption. During the period from day 20 to 35 of exposure,
the daily dry food consumption per rat was 28± 1.1 g for the
CIH rats and 28± 0.8 g for the sham-treated rats (this does not
account for food spill into bedding or any additional consump-
tion of the corn bedding itself, but there is no reason to assume
that these would differ between CIH- and sham-treated rats).
The same rats had during this period a daily body weight gain
of 1.8± 0.2 and 3.4± 0.3 g/day, respectively (p< 0.004), and the
body weight gain per gram of food consumed was 0.066± 0.008
and 0.120± 0.009 g, respectively (p< 0.002). Thus, the reduced
rate of body weight gain in the CIH rats was related to a signiﬁ-
cantly highermetabolism and energy expenditure when compared
to the sham-treated rats.
To assess the extent to which CIH exposure disrupted sleep,
a total of 10 h of direct observation of awakenings occurring in
relation to O2 cycling was conducted with group-housed rats on
days 10–15 of exposure. Arousals were noted (scored) if any rat in
the group of three opened the eyes or lifted the head during the
hypoxic phase of the cycle. The observations revealed that CIH
rats slept through 62% the hypoxic phases of the cycle (124 out
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of 200 cycles), whereas sham-treated rats had signiﬁcantly more
hypoxic cycles during which no signs of arousal were noted (79%,
or 158 out of 200 cycles; Pearson’sχ2 = 13.9, p = 0.0002 for differ-
ence between the two proportions). Although the approach that
we used overestimated the amount of sleep disruption because
awakening of any one rat in the group was treated as an awakening
of the entire group, these observations suggest that sleep was more
fragmented in the CIH rats. On the other hand, it is clear that both
groups were able to sleep through more than a half of the real and
sham O2 nadirs.
Within each exposure group, the CIH rats had consistently
lower weights of the heart and left ventricle (Table 1). The differ-
ence was signiﬁcant in the 35-day exposure group (p< 0.004 for
the heart and p< 0.0025 for the left ventricle), but disappeared in
the group normally housed for an additional 35 days after 35-day
exposure. The differences in the heart weight was not statistically
signiﬁcant when it was scaled by body weight, whereas the scaled
by body weight left ventricular weight was still signiﬁcantly lower
in the CIH than sham-treated rats of the 35-day exposure group
(p< 0.02). Thus, there was no evidence of heart hypertrophy in
the CIH rats.
The adrenal gland weight did not differ between the CIH
and sham-treated rats exposed to CIH/sham treatments for 7,
21, or 35 days. In the rats normally housed for 35 days after 35-
day exposure, the adrenal glands were signiﬁcantly larger in the
sham-treated group than in the group earlier subjected to CIH
(p< 0.03). This could represent a continuation of the trend also
seen in the 35-day exposure group, a trend that could be a net result
of a gradual adaptation to CIH and generally higher weights of all
measured organs in the sham-treated rats. The same trend per-
sisted when the adrenal gland weights were scaled by body weight,
but the difference was not statistically signiﬁcant. It is also of note
that the rats subjected to sham treatment for 35 days with the con-
current daily administration of losartan had much smaller adrenal
glands that those subjected for 35 days to sham treatment only
(p< 0.015; Holm–Sidak-corrected comparison across all groups).
BLOOD PRESSURE, HEART RATE, RESPIRATORY RATE, AND
HEMATOCRIT AFTER DIFFERENT PERIODS OF EXPOSURE TO CIH OR
SHAM TREATMENT
The systolic arterial blood pressure measured under urethane
anesthesia on the next day after termination of exposures was
signiﬁcantly higher in the CIH than sham-treated rats only in
the group exposed to CIH for 7 days (Table 2). The rats receiv-
ing losartan generally had lower blood pressure than any other
group (p< 0.04 vs. the 35-day CIH group without losartan, and
p< 0.006 vs. the 35-day sham-treated group without losartan).
The CIH rats of the losartan cohort also tended to have a higher
systolic blood pressure than their sham-treated mates and had
a signiﬁcantly higher heart rate than the sham-treated animals
(p< 0.04). Other than that, there were no differences in the arter-
ial blood pressure or heart rate between the CIH and control rats
(Table 2). In each exposure group, the respiratory rate was con-
sistently lower in the CIH rats, although the difference was not
statistically signiﬁcant (Table 2).
The hematocrit was slightly higher in the CIH than sham-
treated rats of each exposure group, but the difference was not Ta
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signiﬁcant in any group, or when exposure groups were combined
in various conﬁgurations (Table 2).
BASAL LEVELS OF INSULIN, C-PEPTIDE, GLUCOSE, CORTICOSTERONE,
AND RELATED INDICES AFTER CIH/SHAM EXPOSURES
The basal level of insulin measured under anesthesia at the begin-
ning of the ivggt experiment tended to be lower in the CIH
than sham-treated rats within each exposure group, including
the groups housed in normal environment following 35 days of
CIH or sham exposure. The differences between the CIH and
sham-treated rats did not reach statistical signiﬁcance for any one
exposure period but two-wayANOVA applied to the 7, 21, and 35-
day exposure groups revealed a signiﬁcant effect of the treatment
(p = 0.016, F1,2,45 = 6.3). Across the 7, 21, 35, and 35+ 35 days of
normal housing groups, the effect of exposure duration on the
basal insulin level (which included also the effects of age and body
mass)was highly signiﬁcant (p< 0.001,F1,3,52 = 12.18),withmul-
tiple individual differences also being signiﬁcant (within CIH rats:
7 vs. 21 and 7 vs. 35+ 35 days; within sham rats: 7 vs. 21, 7 vs. 35, 7
vs. 35+ 35, and 35 vs. 35+ 35 days). The same trends and similar
signiﬁcance levels were revealed by two-wayANOVA for c-peptide
(the main metabolite of insulin). Linear regression analysis also
revealed that c-peptide levels were tightly correlated with insulin
levels on a sample-by sample basis (p< 0.001, F45 = 26.7), which
conﬁrmed that any degradation of insulin during sample handling
was negligible. Within the 35-day exposure group, c-peptide level
approached a signiﬁcantly lower level in the CIH rats (p = 0.055).
The basal plasma glucose levels tended to be higher in the CIH
than sham-treated rats in all exposure groups, but the differences
were not signiﬁcant within any one exposure group or when the
groups were combined in various combinations. As a result of the
trend for decreased basal insulin levels and increased glucose lev-
els in the CIH rats, the glucose-to-insulin ratio was signiﬁcantly
higher in the CIH than sham-treated rats of the 35-day exposure
group (Table 3).
The HOMA index (an index clinically used for assessment of
the effectiveness of insulin action and calculated as the product of
glucose in millimoles and insulin in milliunits per liter divided by
22) consistently tended to be lower in the CIH than sham-treated
rats of each exposure group, but no signiﬁcant differences were
detected. As expected, the basal levels of insulin and HOMA index
tended to gradually increase with age and body weight (Table 3).
In all exposure groups, corticosterone levels tended to be
slightly higher in the CIH than in the corresponding sham-treated
groups. However, the differences were not statistically signiﬁcant
within any one exposure period (Table 3), and two-way ANOVA
did not reveal any signiﬁcant effect of CIH vs. sham treatment
across all exposure groups.
GRADUAL DEVELOPMENT OF SUPPRESSED GLUCOSE-STIMULATED
INSULIN RELEASE WITH THE DURATION OF EXPOSURE TO CIH AND
RECOVERY AFTER RETURN TO NORMAL HOUSING
It has been shown that the time-course of the insulin response
to glucose load is similar in anesthetized and unanesthetized rats
(Latour and Lautt, 2002), and that an ivgtt study conducted under
anesthesia can detect age-dependent reductions in glucose clear-
ance (Natalucci et al., 2003). Based on those ﬁndings, we chose Ta
b
le
3
|B
as
el
in
e
in
su
lin
,g
lu
co
se
,a
n
d
se
le
ct
ed
h
o
rm
o
n
e
le
ve
ls
in
C
IH
an
d
sh
am
-t
re
at
ed
ra
ts
.
E
xp
o
su
re
d
u
ra
ti
o
n
an
d
ad
d
it
io
n
al
co
n
d
it
io
n
s
7
d
ay
s
21
d
ay
s
35
d
ay
s
35
+
35
d
ay
s
o
f
n
o
rm
al
h
o
u
si
n
g
35
d
ay
s
+
d
ai
ly
lo
sa
rt
an
V
ar
ia
b
le
(u
n
it
s)
C
IH
(m
ea
n
±
S
E
)
(N
)
S
h
am
-t
re
at
ed
(m
ea
n
±
S
E
)
(N
)
C
IH
(m
ea
n
±
S
E
)
(N
)
S
h
am
-t
re
at
ed
(m
ea
n
±
S
E
)
(N
)
C
IH
(m
ea
n
±
S
E
)
(N
)
S
h
am
-t
re
at
ed
(m
ea
n
±
S
E
)
(N
)
C
IH
(m
ea
n
±
S
E
)
(N
)
S
h
am
-t
re
at
ed
(m
ea
n
±
S
E
)
(N
)
C
IH
(m
ea
n
±
S
E
)
(N
)
S
h
am
-t
re
at
ed
(m
ea
n
±
S
E
)
(N
)
In
su
lin
(I;
ng
/m
l)
1.
4
±
0.
2
(9
)
1.
7
±
0.
2
(7
)
2.
3
±
0.
4
(6
)
2.
9
±
0.
1
(6
)
2.
0
±
0.
2
(9
)
2.
5
±
0.
3
(9
)
3.
2
±
0.
6
(7
)
4.
2
±
0.
7
(7
)
1.
8
±
0.
3
(6
)
1.
6
±
0.
1
(6
)
C
-p
ep
tid
e
(p
M
)
14
00
±
15
5
(9
)
17
60
±
13
0
(1
0)
15
05
±
23
0
(4
)
17
92
±
24
0
(5
)
17
80
±
12
0
(9
)
21
70
±
14
0
(1
0)
23
30
±
25
0
(5
)
25
16
±
32
0
(4
)
16
30
±
30
0
(5
)
22
80
±
27
0
(6
)
G
lu
co
se
(G
;m
g/
dl
)
21
3
±
22
(9
)
19
1
±
15
(7
)
22
9
±
20
(7
)
22
1
±
25
(6
)
26
0
±
12
(9
)*
21
6
±
16
(9
)
25
9
±
25
(7
)
24
1
±
19
(7
)
25
9
±
9
(6
)
24
3
±
10
(6
)
G
/I
ra
tio
(m
g/
ng
)
1.
82
±
0.
38
(9
)
1.
21
±
0.
15
(7
)
0.
74
±
0.
07
(6
)
1.
14
±
0.
24
(6
)
1.
45
±
0.
17
(9
)*
0.
94
±
0.
11
(9
)
0.
96
±
0.
16
(7
)
0.
68
±
0.
12
(7
)
1.
59
±
0.
18
(6
)
1.
58
±
0.
08
(6
)
H
O
M
A
(m
U
/l·m
M
)
20
±
2
(9
)
23
±
2
(7
)
39
±
10
(6
)
47
±
6
(6
)
36
±
3
(9
)
39
±
5
(9
)
59
±
13
(7
)
73
±
14
(7
)
27
±
2
(6
)
33
±
6
(6
)
C
or
tic
os
te
ro
ne
(n
g/
m
l)
71
2
±
45
(8
)
68
2
±
55
(1
0)
70
3
±
60
(5
)
61
9
±
50
(7
)
77
0
±
45
(1
0)
71
0
±
40
(1
0)
72
4
±
40
(7
)
67
6
±
80
(6
)
64
0
±
60
(6
)
59
0
±
25
(6
)
*
–
S
ig
ni
ﬁc
an
tly
di
ffe
re
nt
fr
om
sh
am
-t
re
at
ed
an
im
al
s
w
ith
in
th
e
sa
m
e
ex
po
su
re
gr
ou
p
at
p
<
0.
05
(u
np
ai
re
d
t-
te
st
s)
;a
rt
er
ia
lb
lo
od
sa
m
pl
in
g
co
nd
uc
te
d
un
de
r
ur
et
ha
ne
an
es
th
es
ia
.
www.frontiersin.org April 2012 | Volume 3 | Article 51 | 5
Fenik et al. CIH exposure, losartan, and glucoregulation
to conduct the ivgtt under anesthesia in an attempt to reduce the
inter-subject variability of hormonal measures caused by behav-
ioral factors. In retrospect, although we were able to detect a
consistent and progressive reduction of glucose-stimulated insulin
release with increasing durations of exposure to CIH,we found the
inter-subject variability to be still considerable despite anesthesia.
Figure 1 shows one data set for plasma glucose and insulin curves
obtained from the ivgtt conducted under anesthesia with nine rats
subjected to CIH for 35 days and the corresponding group of nine
rats subjected to sham treatment. Despite substantial variability,
the glucose clearance curves show an elevation of glucose levels
in the CIH rats and the insulin curves point to both a general
downward shift in the CIH rats and a clearly reduced second peak
of insulin release (between 11 and 25min after the glucose bolus
injection at time 0).
Figure 2 shows the average time-course of plasma glucose levels
during the ivgtt obtained from animal groups subjected to CIH or
sham treatment for different periods. The total numbers of ani-
mals from which complete ivgtt data were obtained are lower than
the numbers of animals from which the general characteristics of
FIGURE 1 | Individual glucose and insulin curves obtained from the
ivgtt conducted under anesthesia with nine rats subjected to CIH and
nine rats subjected to sham gas exchanges for 35days. Glucose bolus
(400mg/kg) was injected at time zero. Note a clear elevation of glucose
levels in CIH rats (A) and both a downward shift and reduced second peak
of insulin release in CIH rats (between 11 and 25min after glucose bolus
injection) (B).
each group are reported in Table 1 because the ivgtt test was either
not fully successful or not all necessary glucose and insulin mea-
surements were obtained from all animals. Ultimately, complete
ivgtt data were obtained from eight CIH and seven sham rats of
the 7-day exposure group, six CIH and six sham rats of the 21-
day exposure group, nine CIH and nine sham rats of the 35-day
exposure group, and seven CIH and seven sham rats of the 35-
day exposure group that was subsequently housed under normal
conditions for another 35 days before the ivgtt.
Glucose clearance was visibly delayed in the CIH compared to
sham-treated rats of the 7-day group, but only the glucose levels
measured at 70min after glucose bolus injection were signiﬁcantly
different (Figure 2A). Elevation of the glucose level in the CIH rats
of this group was due, in part, to a slight elevation of the baseline
glucose levels in the CIH rats prior to the glucose bolus injection.
In the 21-day group, no difference was detected (Figure 2B). In the
35-day group, the elevation of glucose levels in the CIH rats was
signiﬁcant at three different time points after glucose injection. As
in the 7-day exposure group, this was, at least in part, secondary
to the signiﬁcantly higher baseline glucose level in the CIH ani-
mals (Figure 2C). In the rats housed in a normal environment
for 35 days following 35-day exposures, the glucose curves were
nearly identical in the CIH- and sham-treated rats (Figure 2D).
Thus, the glucose clearance curves did not point to a major dif-
ference between CIH and sham-treated rats other than those that
might have been related to different baseline plasma glucose levels.
In contrast to the relatively modest statistical signiﬁcance of the
effect of CIH on glucose clearance curves, the glucose-stimulated
insulin release exhibited large differences between the CIH and
sham rats that progressed with the duration of exposure. Figure 3
shows the average time-course of plasma insulin levels during ivgtt
that correspond to the glucose curves shown in Figure 2. Whereas
the baseline insulin levels differed little, the post-glucose injec-
tion insulin levels were signiﬁcantly depressed in the CIH rats.
The effect was signiﬁcant at 4–9 different post-glucose time points
in the 7-, 21-, and 35-day exposure groups (Figures 3A–C). In
all these groups, the primary peak, at 1min post-glucose bolus,
was consistently lower (signiﬁcant in the 21-day group), and the
secondary peak was nearly abolished in CIH rats of all exposure
groups. Remarkably, the glucose-stimulated insulin curves were
nearly identical in the CIH and sham rats that were normally
housed for 35 days after 35 days of exposure (Figure 3D). Thus,
the depression of insulin release detected 1 day after the 7–35 days
of CIH was entirely absent following 35 days of housing under
normal conditions.
To further examine the time-course of suppression of the sec-
ondary peak of glucose-stimulated insulin release during the ivgtt,
we calculated the difference between the mean insulin levels dur-
ing the period 11–25min after the glucose bolus and the baseline
insulin level (samples collected 2 and 5minprior to glucose bolus).
These results are shown in Figure 4.Whereas the sham-treated rats
had a continuous trend for an increase of the mean insulin levels
during the secondary peak with the duration of exposure (this
includes age and body weight effects), the CIH rats had continu-
ously and steadily suppressed the secondary insulin peaks across
all periods of exposure. As a result, the difference between the
CIH and sham-treated rats progressively increased and reached
Frontiers in Neurology | Sleep and Chronobiology April 2012 | Volume 3 | Article 51 | 6
Fenik et al. CIH exposure, losartan, and glucoregulation
FIGURE 2 | Average time-course of plasma glucose clearance during the
ivgtt conducted following 7, 21, 35days of exposure to CIH or sham
treatment and in rats subjected to CIH/sham treatment for 35days and
then normally housed for another 35days. Glucose clearance was delayed
in the rats exposed to CIH for 7 days (A) and those subjected to CIH for
35 days (C), but not in the rats subjected to CIH for 21 days (B). The effect
was mainly related to the elevation of baseline glucose levels in the CIH rats
prior to glucose bolus injection (at time zero). In the rats subjected to CIH or
sham treatment for 35 days and then housed normally for another 35 days,
the glucose clearance curves did not differ between CIH and sham-exposed
rats (D). *Indicates p<0.05 relative to the corresponding sham-treated group
at the same time point.
statistical signiﬁcance after 35 days of exposure. The suppression
of the secondary insulin peak was apparently relieved during the
35 day period when the rats earlier exposed to CIH for 35 days
were returned to normal housing because the mean insulin level
during the secondary peak of the response more than doubled in
this group when compared with any of the groups tested 1 day
after termination of CIH exposure lasting from 7 to 35 days.
GLUCOSE CLEARANCE AND INSULIN RELEASE IN RATS TREATED WITH
LOSARTAN DURING EXPOSURE TO CIH
To test whether suppressed insulin release and the associ-
ated impairment of glucose clearance during the ivgtt depend
on renal mechanisms and increased levels of circulating cate-
cholamines/angiotensin (Fletcher et al., 1999),we exposed another
group of rats to CIH or sham treatment for 35 days while also
administering losartan daily. In contrast to the 35-day exposure
group not treated with losartan, both the glucose clearance and
insulin release curves obtained from the rats treated with losartan
were nearly identical between CIH and sham rats (Figure 5). Also
unlike the rats exposed to CIH without losartan (Figure 3C), the
CIH-exposed rats of the losartan group had a clearly identiﬁable
secondary peak of insulin release (Figure 5B). Thus, the differen-
tial effect of CIH vs. sham treatment on glucose and insulin curves
was entirely abolished by losartan.
Although the difference between CIH and sham-treated rats
was absent in the losartan group, the ivgtt curves obtained from
the losartan-treated rats were not identical to those from the
sham-treated rats of the 35-day exposure group not treated with
losartan. The losartan group had an elevated baseline glucose level
(signiﬁcant for the ﬁrst sample during the ivgtt; see Figure 5A),
and the insulin curves obtained from the losartan rats were shifted
downward, including the baseline samples, compared with the
sham-treated rats without losartan (Figure 5B). Thus, while there
was no distinct suppression of glucose-stimulated insulin release
in the CIH–losartan rats, the rats of the losartan group had an
altered set-point for the regulation of glucose and insulin levels.
They were able to more effectively clear excess glucose while main-
taining lower baseline insulin levels and higher glucose levels than
in the sham-treated rats that did not receive losartan. This points
to improved insulin sensitivity in the losartan-treated rats. It is
of note that the losartan rats tended to have lower body weights
and lower HOMA indices than the rats of the 35-day exposure
group without losartan (Tables 1 and 3), a result also consistent
with improved insulin sensitivity. Furthermore, the lower adrenal
gland weights and lower arterial blood pressure (Tables 1 and
2) suggest reduced catecholamine levels and lower sympathetic
activity in the losartan rats.
DISCUSSION
Our main ﬁndings are: (1) that glucose-stimulated insulin release
is suppressed in rats exposed to CIH; (2) that the impairment
progressively increases with the duration of exposure but does
not persist after cessation of CIH; and (3) that a daily treatment
with losartan entirely prevents the suppressant effect of CIH on
counter-regulatory insulin response during the ivgtt. While our
data point to a distinct inhibitory effect of CIH on stimulated
insulin release and the contribution of angiotensin and/or cat-
echolamines to this process, our data do not provide evidence
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FIGURE 3 | Average time-course of glucose-stimulated insulin release
during the ivgtt conducted following 7, 21, 35days of exposure to CIH or
sham treatment and in rats subjected to CIH/sham treatment for 35days
and then normally housed for another 35days.While there were only
minor differences in the baseline insulin levels between the CIH and
sham-treated rats, the differences between insulin levels during the second
phase of insulin release (11–25min after glucose bolus) were large and
increased with the duration of CIH exposure (A–C). This was due to a
profound suppression of the second insulin peak in the CIH rats of all groups
while the second insulin peak in the sham-treated rats increased with the
duration of exposure. In the rats subjected to CIH or sham treatment for
35 days and then housed normally for another 35 days, glucose-stimulated
insulin release did not differ between CIH and sham-exposed rats, with both
groups having a distinct second peak of insulin release (D). *, +Indicate
p<0.05 and p<0.02, respectively, relative to the corresponding
sham-treated group at the same time point. See text for further discussion.
FIGURE 4 | Baseline-adjusted mean insulin levels measured during the
second peak of insulin response (11–25min after glucose bolus) in rats
exposed to CIH or sham treatment for 7, 21, or 35days and in rats
subjected to CIH/sham treatment for 35days and then normally
housed for another 35days.The deﬁcit of insulin release in CIH rats
gradually increased with the duration of exposure due to profound and
steady suppression of insulin release in CIH rats of all groups and gradually
increasing insulin release in the corresponding groups of sham-treated rats.
The difference reached statistical signiﬁcance after 35 days of exposure. The
rats subjected to CIH for 35 days and then normally housed for another
35 days did not have suppressed insulin release and did not differ from any
of the sham-treated groups.
for reduced insulin sensitivity in the CIH rats in which recur-
rent hypoxic episodes occur without other major factors and
conditions typical of OSA inhumans, such as severe sleep fragmen-
tation, large intrathoracic pressure swings or concurrent obesity.
It appears that CIH rats had relatively normal insulin sensitivity, as
suggested by the trend toward lower HOMA indices and only min-
imally reduced glucose clearance after adjustment for the altered
baseline glucose levels. However, the strongly impaired ability to
release insulin in response to glucose load that we found in CIH
rats represents a risk factor for ineffective glucose clearance at
times of high-sugar intake. This deﬁciency alone may facilitate
the occurrence of type 2 diabetes in OSA patients exposed to a
high-sugar diet.
CIH EXPOSURES USED IN OUR STUDY
Our CIH protocol was nominally similar to that used in several
previous studies (e.g., Greenberg et al., 1999; Kraiczi et al., 1999; Li
et al., 2003), but different chamber designs and controller settings
are likely to yield different O2 proﬁles. Indeed, actual O2 proﬁles
used in different studies are relatively rarely described; the O2 pro-
ﬁle that we use has been previously illustrated (Rukhadze et al.,
2010). It is of note that our O2 proﬁle included an overshoot at the
onset of the normoxic half-cycle, which may have helped restore
oxygen saturation after each hypoxic half-cycle. Possibly due to
this effect, our rats did not exhibit any signs typically associated
with prolonged exposure to steady hypoxia, such as signiﬁcantly
increased hematocrit or heart hypertrophy.
Data from CIH studies in rodents suggest that, in addition to
O2 nadirs, other parameters of exposure, such as the cycle length
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FIGURE 5 | Mean glucose and insulin curves obtained from the ivgtt
conducted under anesthesia with six rats subjected to CIH and six rats
subjected to sham gas exchanges for 35days with concurrent daily
administration of the angiotensin type 1 receptor antagonist, losartan.
Losartan treatment eliminated all differences between CIH and
sham-treated rats that occurred following CIH exposures of the same or
shorter durations without losartan. Losartan also shifted upward the
baseline glucose level and shifted downward the baseline insulin level
when compared to the rats sham-exposed for 35 days without losartan
[blue lines in (A) and (B)]. Thus, insulin sensitivity was improved in
losartan-treated animals. See text for further discussion.
or exposure duration, produce qualitatively and quantitatively dif-
ferent outcomes. The results also varywith the genetic background
of the animals (Fletcher et al., 1992, 1999; Kraiczi et al., 1999; Ger-
mack et al., 2002; Polotsky et al., 2003; Nair et al., 2011a), and
likely depend on the interval between the last exposure and the
time of testing. The outcomes from studies in which CIH expo-
sures lasted about 30 days, suggest that severe CIH (O2 nadirs of
5% or less) leads to pulmonary and systemic hypertension, right
ventricular hypertrophy and increased hematocrit (Fletcher et al.,
1992, 1999; Lesske et al., 1997; Fagan, 2001;McGuire andBradford,
2001; Kalaria et al., 2004; Campen et al., 2005; reviewed by Foster
et al., 2007), as well as damage to selected groups of wake-active
neurons (Veasey et al., 2004). However, blood pressure increases
are relativelymodest (often of the order of 10mmHg) and the con-
comitant increases in circulating catecholamine levels are difﬁcult
to detect even when the hypoxic phase of the cycle is relatively
severe and when measurements are conducted immediately after
the exposure (Lesske et al., 1997; Fletcher et al., 1999;Campen et al.,
2005). In healthy humans exposed to mild CIH for 14–28 days,
arterial blood pressure measured after exposure was signiﬁcantly
increased, but the average magnitude of the increase was of the
order of only 3–4mmHg (Gilmartin et al., 2010; Tamisier et al.,
2011), and a recent longitudinal study did not ﬁnd a signiﬁcant
correlation between OSA and arterial hypertension after correc-
tion for age and body mass (Cano-Pumeranga et al., 2011). Some
studies in rodents also reported less dramatic changes in baseline
cardiovascular and cognitive parameters (Greenberg et al., 1999;
Kraiczi et al., 1999; Reeves et al., 2003;Naghshin et al., 2009;Knight
et al., 2011), but it is not clear whether the lesser magnitude of the
effectswas related to less severe hypoxia (nadirs of 6–10%)or other
factors. It is also of note that numerous studies report a positive
effect of CIH on endurance, resistance to ischemic injury, glucose
disposal, and hypertension (Mohan et al., 2001; Cai et al., 2003;
Chiu et al., 2004; Serebrovskaya et al., 2008; Lyamina et al., 2011;
Tonini et al., 2011), but the CIH protocols used to achieve these
beneﬁcial effects often involve less frequent cycling and less severe
hypoxia than those used in studies that aim to model the periodic
O2 desaturations that occur in OSA patients.
Our CIH rats gained weight during the exposure, and did not
have increased hematocrit levels or cardiac hypertrophy. There
was,however, a trend toward an increased heart rate in theCIH rats
and/or arterial blood pressure tended to be increased, consistent
with increased catecholamine levels and/or sympathetic activity
(Lesske et al., 1997; Iiyori et al., 2007; Zoccal et al., 2007; Gilmartin
et al., 2010; Tamisier et al., 2011). The CIH animals appeared
healthy throughout the period of exposure, and the levels of cor-
ticosterone were not different between CIH and sham-treated rats
when measured under anesthesia 1 day after termination of expo-
sure. Collectively, our measures and observations suggest that our
CIH exposures were relatively moderate and not associated with
major stress or sleep disruption (cf. Boss et al., 2005).
The slower rate of body weight gain in our CIH rats was likely
caused by an increased metabolism, rather than reduced food con-
sumption. The increased work of breathing required of CIH rats
must have increased their metabolic rate and could contribute to
their being consistently leaner than sham-treated animals. Con-
sistent with this interpretation, we found that the daily amounts
of food consumed were not signiﬁcantly different between the
CIH and sham-treated rats but were signiﬁcantly higher in the
CIH rats when scaled by the body weight. The additional respi-
ratory effort required of CIH rats could have beneﬁcial effects on
their endurance and/or insulin sensitivity similar to that ascribed
to daily exercise or hypoxic training (Bernardi, 2001; Henriksen,
2007). It is noteworthy that the HOMA index did not suggest
reduced insulin sensitivity in CIH rats. The effect of CIH on the
basal levels of glucose and insulin exhibited relatively weak sta-
tistical signiﬁcance and could be secondary to the body weight
differences between the CIH and sham-treated rats (Bagdade et al.,
1967). On the other hand, the signiﬁcantly increased baseline
glucose-to-insulin ratio in the 35-day exposure group suggested
an altered set-point for the regulation of the steady-state glucose
level.
One caveat with our ivgtt study is that it was conducted
under anesthesia because anesthesia elevates the baseline glucose
www.frontiersin.org April 2012 | Volume 3 | Article 51 | 9
Fenik et al. CIH exposure, losartan, and glucoregulation
and insulin levels compared with those in behaving animals
(Netchiporouk et al., 2001). This could modify the time-course of
cellular events that lead to insulin release following glucose injec-
tion. Nevertheless, our sham-treated and CIH rats were compared
under the same experimental conditions; thus, any differences
between the groups must have been related to the exposure to
CIH. Furthermore, the major suppression of glucose-stimulated
insulin release that we consistently observed in CIH-exposed rats
was absent after a period of normal housing and in the losartan-
treated rats. Thus, while the anesthetic might have modiﬁed the
time-course and magnitude of glucose and insulin changes during
the ivgtt, we were able to uncover a distinct impairment of insulin
release that was directly related to the exposure to CIH.
REDUCED COUNTER-REGULATORY RESPONSE TO GLUCOSE LOAD IN
CIH RATS
When challenged with a glucose load, our CIH rats had a precipi-
tously reduced second phase of insulin response, a reduction that
was also signiﬁcant after correction for the slightly lower base-
line insulin levels. In humans, a reduced compensatory response
to glucose load better distinguishes between potentially diabetic
and non-diabetic individuals than the baseline glucose and insulin
values (Bagdade et al., 1967). Thus, our ﬁndings from the ivgtt
tests suggest that CIH altered the mechanisms of insulin release
in a manner that would put the CIH rats at risk of prolonged
hyperglycemia under conditions of elevated sugar intake.
Our results are different from those with CIH exposures of
lean and leptin-deﬁcient (obese) mice (Polotsky et al., 2003; Li
et al., 2005). In those studies, following 5-day exposures, both the
lean and obese mice had reduced fasting glucose levels, whereas
insulin levels were increased in the obese but unchanged in the
lean animals. Under the same conditions, both lean and obese
mice exposed to either CIH or sham treatment had a signiﬁcant
decrease of body weight and reduced food intake. In addition,
the lean mice exhibited signs of hyperlipidemia (Li et al., 2005),
which was then found to also occur following 4-week exposures
to severe (O2 nadir of 5%), but not moderate CIH (Li et al.,
2007). After 5-day exposures, both normal and leptin-deﬁcient
mice had improved glucose clearance during an intraperitoneal
glucose-tolerance test. Thus, they did not exhibit the insulin resis-
tance found in lean mice acutely subjected to CIH for 9 h and
then tested during the exposure (Iiyori et al., 2007). In contrast,
substantially longer (12weeks) exposures yielded outcomes that
were more compatible with our study (Polotsky et al., 2003). Lean
mice exposed to either CIH or sham treatment for 12weeks had
similar body weight gains and food consumption, and the fasting
glucose levels tended to be higher in the CIH than control animals,
but the glucose responsiveness of these mice was not tested. Thus,
considering that lean and obese mice responded differently to glu-
cose load after 5 days of exposure, the effect of long-term exposure
of normal animals on glucoregulation could not be inferred from
that study.
MECHANISMS UNDERLYING THE CIH-INDUCED SUPPRESSION OF
STIMULATED INSULIN RELEASE
The reduced insulin release in CIH rats could suggest a diminished
availability of insulin, but experimental data do not support this.
Both apoptosis and proliferation of pancreatic β-cells occur in rats
and mice exposed to CIH, with the net effect being an increased
pancreatic insulin reserve (Kubin et al., 2006;Yokoe et al., 2008; Xu
et al., 2009). Thus, it is more plausible that rodents exposed to CIH
had impaired insulin release, rather than reduced insulin avail-
ability. Since rodents exposed to CIH have increased sympathetic
activation and increased levels of circulating catecholamines, it
is likely that the reduced insulin release in CIH rats was caused
by inhibition exerted by the sympathetic system at the pancre-
atic β-cell level. Although impaired insulin-dependent transport
of glucose into skeletal muscles could contribute to the difference
between CIH- and sham-treated rats in our study (further dis-
cussed below in the context of losartan effects), it is of note that
stimulated insulin release was also suppressed in healthy humans
acutely exposed to CIH (Louis and Punjabi, 2009). In our experi-
ments, the second phase of stimulated insulin release was similarly
suppressed after 7, 21, and 35 days of exposure. Accordingly, the
progressive increase of insulin release associated with increasing
body mass and age in sham rats was probably the main reason
for the increasing with the period of exposure difference between
the CIH and sham rats. Thus, at least in healthy humans and
rodents, suppression of stimulated insulin release may be the ﬁrst
and most prominent effect of CIH. Indeed, impaired counter-
regulatory response to glucose load is a major ﬁrst step toward the
development of type 2 diabetes (Weyer et al., 1999).
Chronic sustained hypoxia causes elevation of tyrosine hydrox-
ylase expression and activity in selected brain regions (Pépin et al.,
1996; Gozal et al., 2005). In contrast, following CIH, despite the
evidence for increase sympathetic activation and increased circu-
lating catecholamine/angiotensin II levels, brain tyrosine hydrox-
ylase levels and activity are minimally affected (Li et al., 1996;
Gozal et al., 2005). This suggests that CIH exerts its effects mainly
on catecholaminergic output neurons of the sympathetic system.
However,we recently found evidence for both structural and func-
tional enhancements of noradrenergic transmission in the brain-
stem of CIH-exposed rats. Speciﬁcally, exposure to CIH resulted
in sprouting of noradrenergic terminals in different sensory and
motor regions within the lower brainstem (Rukhadze et al., 2010;
Mody et al., 2011) and increased endogenous noradrenergic acti-
vation of cranial motoneurons (Stettner et al., 2012). Data also
suggest that activity of dorsal medullary catecholaminergic neu-
rons is increased 1 day after 7-day exposure to CIH (Knight et al.,
2011). Thus, CIH may cause noradrenergic hyperactivity both
centrally and peripherally that outlasts the period of exposure.
Abolition of the detrimental effects of CIH on glucose-stimulated
insulin release in the rats treated with losartan supports a role
of catecholamines and angiotensin in this process, but it remains
to be determined whether both central and peripheral neurohu-
moral controls of pancreatic β-cells are affected and for how long
this change can persist.
INTERACTION OF CIH AND SLEEP RESTRICTION – RELEVANCE TO OSA
Different pathogenic conditions of OSA, such as CIH, sleep loss,
sleep fragmentation, and large intrathoracic pressure swings, may
exert distinct deleterious effects on cardiorespiratory and meta-
bolic functions (Dimsdale et al., 1997; Lévy et al., 2008; Tasali and
Ip, 2008). Among those, the effects of CIH and sleep disruptions
Frontiers in Neurology | Sleep and Chronobiology April 2012 | Volume 3 | Article 51 | 10
Fenik et al. CIH exposure, losartan, and glucoregulation
may have additive effects because changes qualitatively similar to
those in our study were observed in healthy young adults sub-
jected to chronic sleep restriction (Spiegel et al., 1999). Speciﬁcally,
the subjects had a reduced ability to clear glucose during ivgtt
and their acute insulin response was reduced, while their baseline
glucose and insulin levels were minimally changed. The authors
suggested that the state induced by sleep loss represented an early
stage of insulin resistance. In our CIH rats, sleep fragmentation
may have occurred to a limited extent but, in contrast to OSA
patients, our CIH rats slept through most of the hypoxic phases of
the CIH cycle and their corticosterone level was not signiﬁcantly
elevated.Therefore, the similarity betweenouroutcomes and those
from a study with selective sleep restriction suggests that CIH and
chronic sleep loss may both impede the response to glucose load,
but it is not known to what extent the underlying mechanisms
differ. It is of interest to note that, in mice, both CIH and sleep
fragmentation cause similar cognitive deﬁcits, with nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase playing a role
in both effects (Nair et al., 2011a,b). In OSA patients, who are
often obese, oxidative stress, elevated catecholamines/angiotensin
and fatty acids, and sleep disruption are likely to act in concert
to accelerate and/or exacerbate development of type 2 diabetes
(Evans et al., 2003).
EFFECTS OF CIH IN RATS TREATED WITH LOSARTAN
Daily losartan administration resulted in slower body weight gain,
reduced adrenal gland weight, and lower arterial blood pressure in
both sham- and CIH-treated rats. The insulin response to glucose
load and glucose clearance rate were not different between the two
groups, and the secondary peak of insulin release was not sup-
pressed. However, insulin levels both before and during ivgtt were
lower in the losartan-treated rats than in the rats not treated with
losartan and subjected for 35 days to shamgas exchanges. This sug-
gests that losartan improved insulin sensitivity,as it did in theobese
Zucker rats (Henriksen et al., 2001). Importantly, angiotensin II
antagonism can improve glucose disposal by modulating insulin
receptor/insulin receptor substrate-1 signaling in skeletal mus-
cles, with a convergent action on some of the same intracellular
mechanisms that are also beneﬁcially affected by exercise train-
ing (Henriksen, 2007). Thus, the effects of losartan on glucose
transport in skeletal muscles and the enhanced work of breath-
ing could act together to improve the outcomes in our losartan
rats subjected to CIH. It is, however, of note that several trends
present in the CIH rats of the other exposure groups, such as
reduced body weight gain, reduced heart weight, increased sys-
tolic blood pressure, tachycardia, and reduced respiratory rate,
were still present in the CIH rats treated with losartan. Thus, CIH
exerts its effects throughmultiplemechanisms,of whichonly some
can be directly related to actions mediated by type 1 angiotensin
II receptors.
CONCLUSION
Normal rats exposed to CIH and then tested ∼20 h after the last
exposure (to minimize any acute effects of the treatment) had a
signiﬁcantly and progressively reduced insulin response to glu-
cose load. Extrapolation of these results to OSA patients leads
to the conclusion that a combination of CIH caused by sleep-
disordered breathing with a high-sugar diet may expose these
patients to an increased risk of developing glucose intolerance
and type 2 diabetes. Our ﬁnding that the detrimental effects of
CIH on glucose-stimulated insulin release are reversible after the
animals are returned to normal housing conditions is consistent
with studies in OSA patients in which treatment with continuous
positive airway pressure improved insulin responsiveness (Brooks
et al., 1994; Harsch et al., 2004).
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